[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Asia Pacific Pharmaceutical Manufacturing Industry 2020-2027 by Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country: Trend Forecast and Growth Opportunity

March 2021 | 130 pages | ID: A698267F4955EN
GMD Research

US$ 2,700.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Asia Pacific pharmaceutical manufacturing industry will grow by 14.8% annually with a total addressable market cap of $1,034.6 billion over 2021-2027 driven by increased drug approvals, increasing prevalence of chronic ailments, growing geriatric population, high investment in research and development, and increasing per capita healthcare expenditure amid the COVID-19 pandemic.

Highlighted with 33 tables and 63 figures, this 130-page report “Asia Pacific Pharmaceutical Manufacturing Industry 2020-2027 by Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific pharmaceutical manufacturing industry and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate/forecast from 2020 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:
  • Industry Structure
  • Growth Drivers
  • Restraints and Challenges
  • Emerging Product Trends & Industry Opportunities
  • Porter’s Fiver Forces
The trend and outlook of Asia Pacific industry is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific pharmaceutical manufacturing industry in every aspect of the classification from perspectives of Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country.

Based on Formulation, the Asia Pacific industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
  • Tablets
  • Capsules
  • Injectable
  • Sprays
  • Suspensions
  • Powders
  • Other Formulations
Based on Route of Administration, the Asia Pacific industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
  • Oral Medicine
  • Topical Medicine
  • Parenteral Medicine
  • Inhalations
  • Other Routes of Administration
Based on Age Group, the Asia Pacific industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
  • Children & Adolescents
  • Adults
  • Geriatric
Based on Therapeutic Application, the Asia Pacific industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
  • Cardiovascular Diseases
  • Pain
  • Diabetes
  • Cancer
  • Respiratory Diseases
  • Neurological Diseases
  • Orthopedics
  • Other Applications
Based on Drug Type, the Asia Pacific industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
  • Branded Prescription Drugs
  • Generic Prescription Drugs
  • OTC Drugs
Based on Distribution Channels, the Asia Pacific industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
  • Retail Channels
  • Non-retail Channels
Based on Manufacturing Facility, the Asia Pacific industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
  • In-house Facility
  • Outsourced Facility
Geographically, the following national/local markets are fully investigated:
  • Japan
  • China
  • South Korea
  • Australia
  • India
      • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual production value are available for 2017-2027. The breakdown of key national industry by Formulation, Route of Administration, and Drug Type over the forecast years is also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including industry leaders and important emerging players.

Specifically, potential risks associated with investing in Asia Pacific pharmaceutical manufacturing industry are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request):

Abbott Laboratories

Aenova Group

Amgen

AstraZeneca

Catalent Inc.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Gilead Sciences

GlaxoSmithKline plc

Johnson & Johnson

Lonza Group

Lupin

Merck & Co., Inc.

Novartis AG

Novo Nordisk

Pfizer, Inc.

Roche

Sanofi SA

Takeda

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 INTRODUCTION

1.1 Industry Definition and Research Scope
  1.1.1 Industry Definition
  1.1.2 Research Scope
1.2 Research Methodology
  1.2.1 Overview of Industry Research Methodology
  1.2.2 Industry Assumption
  1.2.3 Secondary Data
  1.2.4 Primary Data
  1.2.5 Data Filtration and Model Design
  1.2.6 Industry Size/Share Estimation
  1.2.7 Research Limitations
1.3 Executive Summary

2 INDUSTRY OVERVIEW AND DYNAMICS

2.1 Industry Size and Forecast
  2.1.1 Impact of COVID-19 on World Economy
  2.1.2 Impact of COVID-19 on the Industry
2.2 Major Growth Drivers
2.3 Industry Restraints and Challenges
2.4 Emerging Opportunities and Industry Trends
2.5 Porter’s Fiver Forces Analysis

3 SEGMENTATION OF ASIA PACIFIC INDUSTRY BY FORMULATION

3.1 Industry Overview by Formulation
3.2 Tablets
3.3 Capsules
3.4 Injectable
3.5 Sprays
3.6 Suspensions
3.7 Powders
3.8 Other Formulations

4 SEGMENTATION OF ASIA PACIFIC INDUSTRY BY ROUTE OF ADMINISTRATION

4.1 Industry Overview by Route of Administration
4.2 Oral Medicine
4.3 Topical Medicine
4.4 Parenteral Medicine
4.5 Inhalations
4.6 Other Routes of Administration

5 SEGMENTATION OF ASIA PACIFIC INDUSTRY BY AGE GROUP

5.1 Industry Overview by Age Group
5.2 Children & Adolescents
5.3 Adults
5.4 Geriatric

6 SEGMENTATION OF ASIA PACIFIC INDUSTRY BY THERAPEUTIC APPLICATION

6.1 Industry Overview by Therapeutic Application
6.2 Cardiovascular Diseases
6.3 Pain
6.4 Diabetes
6.5 Cancer
6.6 Respiratory Diseases
6.7 Neurological Diseases
6.8 Orthopedics
6.9 Other Applications

7 SEGMENTATION OF ASIA PACIFIC INDUSTRY BY DRUG TYPE

7.1 Industry Overview by Drug Type
7.2 Branded Prescription Drugs
7.3 Generic Prescription Drugs
7.4 OTC Drugs

8 SEGMENTATION OF ASIA PACIFIC INDUSTRY BY DISTRIBUTION CHANNELS

8.1 Industry Overview by Distribution Channels
8.2 Retail Channels
8.3 Non-retail Channels

9 SEGMENTATION OF ASIA PACIFIC INDUSTRY BY MANUFACTURING FACILITY

9.1 Industry Overview by Manufacturing Facility
9.2 In-house Facility
9.3 Outsourced Facility

10 ASIA-PACIFIC INDUSTRY 2020-2027 BY COUNTRY

10.1 Overview of Asia-Pacific Industry
10.2 China
10.3 Japan
10.4 India
10.5 Australia
10.6 South Korea
10.7 Rest of APAC Region

11 COMPETITIVE LANDSCAPE

11.1 Overview of Key Vendors
11.2 New Product Launch, Partnership, Investment, and M&A
11.3 Company Profiles
Abbott Laboratories
Aenova Group
Amgen
AstraZeneca
Catalent Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences
GlaxoSmithKline plc
Johnson & Johnson
Lonza Group
Lupin
Merck & Co., Inc.
Novartis AG
Novo Nordisk
Pfizer, Inc.
Roche
Sanofi SA
Takeda

12 INVESTING IN ASIA PACIFIC INDUSTRY: RISK ASSESSMENT AND MANAGEMENT

12.1 Risk Evaluation of Asia Pacific Industry
12.2 Critical Success Factors (CSFs)
Related Reports and Products

LIST OF TABLES

Table 1. Snapshot of Asia Pacific Pharmaceutical Manufacturing Industry in Balanced Perspective, 2020-2027
Table 2. Growth Rate of World Real GDP, 2017-2021
Table 3. Main Product Trends and Industry Opportunities in Asia Pacific Pharmaceutical Manufacturing Industry
Table 4. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn
Table 5. Asia Pacific Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn
Table 6. Asia Pacific Pharmaceutical Manufacturing Industry by Age Group, 2017-2027, $ bn
Table 7. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application, 2017-2027, $ bn
Table 8. Asia Pacific Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn
Table 9. Asia Pacific Pharmaceutical Manufacturing Industry by Distribution Channels, 2017-2027, $ bn
Table 10. Asia Pacific Pharmaceutical Manufacturing Industry by Manufacturing Facility, 2017-2027, $ bn
Table 11. APAC Pharmaceutical Manufacturing Industry by Country, 2017-2027, $ bn
Table 12. China Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn
Table 13. China Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn
Table 14. China Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn
Table 15. Japan Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn
Table 16. Japan Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn
Table 17. Japan Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn
Table 18. India Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn
Table 19. India Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn
Table 20. India Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn
Table 21. Australia Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn
Table 22. Australia Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn
Table 23. Australia Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn
Table 24. South Korea Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn
Table 25. South Korea Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn
Table 26. South Korea Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn
Table 27. Pharmaceutical Manufacturing Industry in Rest of APAC by Country/Region, 2017-2027, $ bn
Table 28. Abbott Laboratories: Company Snapshot
Table 29. Abbott Laboratories: Business Segmentation
Table 30. Abbott Laboratories: Product Portfolio
Table 31. Abbott Laboratories: Revenue, 2017-2019, $ bn
Table 32. Risk Evaluation for Investing in Asia Pacific Industry, 2020-2027
Table 33. Critical Success Factors and Key Takeaways


LIST OF FIGURES

Figure 1. Research Method Flow Chart
Figure 2. Breakdown of Primary Research
Figure 3. Bottom-up Approach and Top-down Approach for Industry Estimation
Figure 4. Asia Pacific Industry Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2027
Figure 5. Asia Pacific Pharmaceutical Manufacturing Industry, 2017-2027, $ bn
Figure 6. Impact of COVID-19 on Business
Figure 7. Primary Drivers and Impact Factors of Asia Pacific Pharmaceutical Manufacturing Industry
Figure 8. Primary Restraints and Impact Factors of Asia Pacific Pharmaceutical Manufacturing Industry
Figure 9. Investment Opportunity Analysis
Figure 10. Porter’s Fiver Forces Analysis of Asia Pacific Pharmaceutical Manufacturing Industry
Figure 11. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Formulation, 2020-2027, % of Revenue
Figure 12. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Formulation, Value ($ bn) and Share (%)
Figure 13. Asia Pacific Pharmaceutical Manufacturing Industry: Tablets, 2017-2027, $ bn
Figure 14. Asia Pacific Pharmaceutical Manufacturing Industry: Capsules, 2017-2027, $ bn
Figure 15. Asia Pacific Pharmaceutical Manufacturing Industry: Injectable, 2017-2027, $ bn
Figure 16. Asia Pacific Pharmaceutical Manufacturing Industry: Sprays, 2017-2027, $ bn
Figure 17. Asia Pacific Pharmaceutical Manufacturing Industry: Suspensions, 2017-2027, $ bn
Figure 18. Asia Pacific Pharmaceutical Manufacturing Industry: Powders, 2017-2027, $ bn
Figure 19. Asia Pacific Pharmaceutical Manufacturing Industry: Other Formulations, 2017-2027, $ bn
Figure 20. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Route of Administration, 2020-2027, % of Revenue
Figure 21. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Route of Administration, Value ($ bn) and Share (%)
Figure 22. Asia Pacific Pharmaceutical Manufacturing Industry: Oral Medicine, 2017-2027, $ bn
Figure 23. Asia Pacific Pharmaceutical Manufacturing Industry: Topical Medicine, 2017-2027, $ bn
Figure 24. Asia Pacific Pharmaceutical Manufacturing Industry: Parenteral Medicine, 2017-2027, $ bn
Figure 25. Asia Pacific Pharmaceutical Manufacturing Industry: Inhalations, 2017-2027, $ bn
Figure 26. Asia Pacific Pharmaceutical Manufacturing Industry: Other Routes of Administration, 2017-2027, $ bn
Figure 27. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Age Group, 2020-2027, % of Revenue
Figure 28. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Age Group, Value ($ bn) and Share (%)
Figure 29. Asia Pacific Pharmaceutical Manufacturing Industry: Children & Adolescents, 2017-2027, $ bn
Figure 30. Asia Pacific Pharmaceutical Manufacturing Industry: Adults, 2017-2027, $ bn
Figure 31. Asia Pacific Pharmaceutical Manufacturing Industry: Geriatric, 2017-2027, $ bn
Figure 32. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application, 2020-2027, % of Revenue
Figure 33. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Therapeutic Application, Value ($ bn) and Share (%)
Figure 34. Asia Pacific Pharmaceutical Manufacturing Industry: Cardiovascular Diseases, 2017-2027, $ bn
Figure 35. Asia Pacific Pharmaceutical Manufacturing Industry: Pain, 2017-2027, $ bn
Figure 36. Asia Pacific Pharmaceutical Manufacturing Industry: Diabetes, 2017-2027, $ bn
Figure 37. Asia Pacific Pharmaceutical Manufacturing Industry: Cancer, 2017-2027, $ bn
Figure 38. Asia Pacific Pharmaceutical Manufacturing Industry: Respiratory Diseases, 2017-2027, $ bn
Figure 39. Asia Pacific Pharmaceutical Manufacturing Industry: Neurological Diseases, 2017-2027, $ bn
Figure 40. Asia Pacific Pharmaceutical Manufacturing Industry: Orthopedics, 2017-2027, $ bn
Figure 41. Asia Pacific Pharmaceutical Manufacturing Industry: Other Applications, 2017-2027, $ bn
Figure 42. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Drug Type, 2020-2027, % of Revenue
Figure 43. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Drug Type, Value ($ bn) and Share (%)
Figure 44. Asia Pacific Pharmaceutical Manufacturing Industry: Branded Prescription Drugs, 2017-2027, $ bn
Figure 45. Asia Pacific Pharmaceutical Manufacturing Industry: Generic Prescription Drugs, 2017-2027, $ bn
Figure 46. Asia Pacific Pharmaceutical Manufacturing Industry: OTC Drugs, 2017-2027, $ bn
Figure 47. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Distribution Channels, 2020-2027, % of Revenue
Figure 48. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Distribution Channels, Value ($ bn) and Share (%)
Figure 49. Asia Pacific Pharmaceutical Manufacturing Industry: Retail Channels, 2017-2027, $ bn
Figure 50. Asia Pacific Pharmaceutical Manufacturing Industry: Non-retail Channels, 2017-2027, $ bn
Figure 51. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Manufacturing Facility, 2020-2027, % of Revenue
Figure 52. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Manufacturing Facility, Value ($ bn) and Share (%)
Figure 53. Asia Pacific Pharmaceutical Manufacturing Industry: In-house Facility, 2017-2027, $ bn
Figure 54. Asia Pacific Pharmaceutical Manufacturing Industry: Outsourced Facility, 2017-2027, $ bn
Figure 55. Breakdown of APAC Pharmaceutical Manufacturing Industry by Country, 2020 and 2027, % of Revenue
Figure 56. Contribution to APAC 2021-2027 Cumulative Revenue by Country, Value ($ bn) and Share (%)
Figure 57. Pharmaceutical Manufacturing Industry in China, 2017-2027, $ bn
Figure 58. Pharmaceutical Manufacturing Industry in Japan, 2017-2027, $ bn
Figure 59. Pharmaceutical Manufacturing Industry in India, 2017-2027, $ bn
Figure 60. Pharmaceutical Manufacturing Industry in Australia, 2017-2027, $ bn
Figure 61. Pharmaceutical Manufacturing Industry in South Korea, 2017-2027, $ bn
Figure 62. Pharmaceutical Manufacturing Industry in Rest of APAC, 2017-2027, $ bn
Figure 63. Growth Stage of Asia Pacific Industrial Robot Software Industry over the Forecast Period


More Publications